Sarepta Therapeutics, Inc. SRPT reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

Roche announced positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys (delandistrogene moxeparvovec), the first approved gene ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene moxeparvovec) in children with the rare muscle-wasting disorder Duchenne ...

Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...

The company’s management has demonstrated exceptional proficiency in launching Elevidys, achieving over 110% quarter-over-quarter growth and surpassing market expectations by approximately 17% ...

Roche Holding AG released its Q4 and full-year ... The likes of gene therapy (for Duchenne Muscular Dystrophy, “DMD”), Elevidys, Lymphoma meds Columvi and Itovebi, and Piasky, developed ...

Nabaparna Bhattacharya Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years Sarepta's EMBARK study confirms Elevidys offers sustained ...

Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.9 million – Achieved GAAP and non-GAAP net income of $159.0 million and $206.0 million for the fourth quarter of ...

of contract manufacturing and other revenues associated with commercial ELEVIDYS supply delivered to Roche and royalty revenue received from Roche, as compared to $9.2 million of contract ...